4//SEC Filing
Donegan Michael C 4
Accession 0001209191-23-004871
CIK 0000025743other
Filed
Jan 24, 7:00 PM ET
Accepted
Jan 25, 5:50 PM ET
Size
23.7 KB
Accession
0001209191-23-004871
Insider Transaction Report
Form 4
Donegan Michael C
Vice President Finance
Transactions
- Exercise/Conversion
Restricted Stock Units
2023-01-23−2,400→ 0 totalExercise: $0.00→ Common Stock (2,400 underlying) - Exercise/Conversion
Common Stock
2023-01-23+380→ 4,934 total - Exercise/Conversion
Restricted Stock Units
2023-01-23−1,066→ 0 totalExercise: $0.00→ Common Stock (1,066 underlying) - Exercise/Conversion
Restricted Stock Units
2023-01-23−519→ 0 totalExercise: $0.00→ Common Stock (519 underlying) - Exercise/Conversion
Common Stock
2023-01-23+1,066→ 6,000 total - Exercise/Conversion
Restricted Stock Units
2023-01-23−380→ 0 totalExercise: $0.00→ Common Stock (380 underlying) - Exercise/Conversion
Common Stock
2023-01-23+519→ 6,519 total - Exercise/Conversion
Common Stock
2023-01-23+2,400→ 8,919 total - Sale
Common Stock
2023-01-23$5.34/sh−1,302$6,950→ 7,617 total - Sale
Common Stock
2023-01-24$5.31/sh−7$37→ 7,610 total
Footnotes (7)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs).
- [F2]The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of ranging from $5.32 through $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
- [F4]The RSUs were to vest in three equal installments annually beginning March 30, 2021 and becoming fully vested on March 30, 2023. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".
- [F5]The RSUs were to vest in three equal installments annually beginning July 1, 2022 and becoming fully vested on July 1, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".
- [F6]Subject to the reporting person's continuous service, the RSUs were to vest in three equal installments annually, beginning September 29, 2022 and becoming fully vested on September 29, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".
- [F7]The RSUs were to vest in three equal installments annually beginning March 23, 2023 and becoming fully vested on March 23, 2025. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".
Documents
Issuer
TherapeuticsMD, Inc.
CIK 0000025743
Entity typeother
Related Parties
1- filerCIK 0001627810
Filing Metadata
- Form type
- 4
- Filed
- Jan 24, 7:00 PM ET
- Accepted
- Jan 25, 5:50 PM ET
- Size
- 23.7 KB